Editorial Commentary
Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond
Abstract
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new glucose-lowering agents that enhance glucosuria independently of insulin (1). They improve glucose control in patients with type 2 diabetes mellitus (T2DM) by reducing both fasting and postprandial hyperglycemia, with a minimal risk of hypoglycemia.
